Keywords: Brazil, Mexico, Reimbursement, Drug costs, Angiogenesis inhibitors, Decision Resources, Avastin, Sutent, Nexavar, Cancer treatment

Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study

Article | 28 March 2012

Print This

Depending on the tumor type, around one-quarter to one-third of surveyed Brazilian and Mexican oncologists’ patients who are eligible ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in